Quantifying the CDK inhibitor VMY-1-103's activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI

Cell Cycle

Volumn 11, Issue 20, 2012, Pages 3801-3809

  Sirajuddin, Paul ^a   Das, Sudeep ^b   Ringer, Lymor ^a   Rodriguez, Olga C ^a   Sivakumar, Angiela ^a   Lee, Yi Chien ^a   Üren, Aykut ^a   Fricke, Stanley T ^c   Rood, Brian ^c   Ozcan, Alpay ^d   Wang, Sean S ^a   Karam, Sana ^e   Yenugonda, Venkata ^e   Salinas, Patricia ^a   Petricoin III, Emanuel ^f   Pishvaian, Michael ^a   Lisanti, Michael P ^g   Wang, Yue ^d   Schlegel, Richard ^a,e   Moasser, Bahram ^b   Albanese, Chris ^a,e   more..

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f GEORGE MASON UNIVERSITY   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Animal models; CDK inhibitor; Medulloblastoma; MR Spectroscopy; MRI; Prostate; Tandem mass spectrometry

Indexed keywords

EID: 84868021546     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.21988     Document Type: Article

References (34)

1. Paternot S, Bockstaele L, Bisteau X, Kooken H, Coulonval K, Roger P P. Rb inactivation in cell cycle and cancer: the puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase. Cell Cycle 2010;9:689-99; PMID:20107323; http://dx.doi.org/10.4161/cc.9. 4.10611.
2. Garrett JT, Chakrabarty A, Arteaga CL. Will PI3K pathway inhibitors be effective as single agents in patients with cancer? Oncotarget 2011;2:1314-21; PMID:22248929.
3. Beloueche-Babari M, Arunan V, Jackson LE, Perusinghe N, Sharp SY, Workman P, et al. Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition. Oncotarget 2010;1:185-97; PMID:21037799.
4. van Vuurden DG, Hulleman E, Meijer OL, Wedekind LE, Kool M, Witt H, et al. PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget 2011;2:984-96; PMID:22184287.
5. You AJ, Jackman RJ, Whitesides GM, Schreiber SL. A miniaturized arrayed assay format for detecting small molecule-protein interactions in cells. Chem Biol 1997;4:969-75; PMID:9427662; http://dx.doi.org/10.1016/S1074-5521 (97) 90305-7. (Pubitemid 28050381)
6. Routledge C, Marsden CA. Recent advances in high-performance liquid chromatographic analysis of small molecules. Application of high-performance liquid chromatography with electrochemical detection to the study of neurotransmitters in vivo. Biochem Soc Trans 1985;13:1058-61; PMID:2419180. (Pubitemid 16178017)
7. Konsoula R, Jung M. In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors. Int J Pharm 2008;361:19-25; PMID:18562136; http://dx.doi.org/10.1016/j. ijpharm.2008.05.001.
8. Ghosh JC, Altieri DC. Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3beta in colorectal cancer cells. Clin Cancer Res 2005;11:4580-8; PMID:15958644; http://dx.doi.org/10.1158/1078-0432. CCR-04-2624. (Pubitemid 40825649)
9. Ringer L, Sirajuddin P, Yenugonda VM, Ghosh A, Divito K, Trabosh V, et al. VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells. Cancer Biol Ther 2010;10:320-5; PMID:20574155; http://dx.doi.org/10.4161/cbt.10.4.12208.
10. Ringer L, Sirajuddin P, Heckler M, Ghosh A, Suprynowicz F, Yenugonda VM, et al. VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medul-loblastoma cells. Cancer Biol Ther 2011;12:818-26; PMID:21885916; http://dx.doi.org/10.4161/cbt.12.9.17682.
11. Yenugonda VM, Deb TB, Grindrod SC, Dakshanamurthy S, Yang Y, Paige M, et al. Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells. Bioorg Med Chem 2011;19:2714-25; PMID:21440449; http://dx.doi.org/10.1016/j.bmc.2011.02.052.
12. Dalvie DK, O'Donnell J P. Characterization of polar urinary metabolites by ionspray tandem mass spectrometry following dansylation. Rapid Commun Mass Spectrom 1998;12:419-22; PMID:9586229; http://dx.doi.org/10.1002/(SICI) 1097-0231 (19980430) 12:8<419::AID-RCM176>3.0. CO;2-S. (Pubitemid 28181280)
13. Beauchamp EM, Ringer L, Bulut G, Sajwan K P, Hall MD, Lee YC, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest 2011;121:148-60; PMID:21183792; http://dx.doi.org/10.1172/JCI42874.
14. Fricke S T, Rodriguez O, Vanmeter J, Dettin LE, Casimiro M, Chien CD, et al. In vivo magnetic resonance volumetric and spectroscopic analysis of mouse prostate cancer models. Prostate 2006;66:708-17; PMID:16425198; http://dx.doi.org/10.1002/pros.20392.
15. Sakamaki T, Casimiro MC, Ju X, Quong AA, Katiyar S, Liu M, et al. Cyclin D1 determines mitochon-drial function in vivo. Mol Cell Biol 2006;26:5449-69; PMID:16809779; http://dx.doi.org/10.1128/MCB.02074-05. (Pubitemid 44036212)
16. Pollock CB, Rodriguez O, Martin PL, Albanese C, Li X, Kopelovich L, et al. Induction of metastatic gastric cancer by peroxisome proliferator-activated receptordelta activation. PPAR Res 2011;2010:571783.
17. Kawabe T, Suganuma M, Ando T, Kimura M, Hori H, Okamoto T. Cdc25C interacts with PCNA at G2/M transition. Oncogene 2002;21:1717-26; PMID:11896603; http://dx.doi.org/10.1038/sj.onc.1205229. (Pubitemid 34259035)
18. Black KL, Ningaraj NS. Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor. Cancer Control 2004;11:165-73; PMID:15153840. (Pubitemid 38758221)
19. Joshi S, Ergin A, Wang M, Reif R, Zhang J, Bruce JN, et al. Inconsistent blood brain barrier disruption by intraarterial mannitol in rabbits: implications for chemotherapy. J Neurooncol 2011;104:11-9; PMID:21153681; http://dx.doi.org/10.1007/s11060-010-0466-4.
20. McDannold N, Vykhodtseva N, Hynynen K. Blood-brain barrier disruption induced by focused ultrasound and circulating preformed microbubbles appears to be characterized by the mechanical index. Ultrasound Med Biol 2008;34:834-40; PMID:18207311; http://dx.doi.org/10.1016/j.ultrasmedbio.2007.10.016. (Pubitemid 351608039)
21. Carman AJ, Mills JH, Krenz A, Kim DG, Bynoe MS. Adenosine receptor signaling modulates permeability of the blood-brain barrier. J Neurosci 2011;31:13272-80; PMID:21917810; http://dx.doi.org/10.1523/JNEUROSCI.3337-11. 2011.
22. Wu JY, Prentice H. Role of taurine in the central nervous system. J Biomed Sci 2010;17(Suppl 1):S1; PMID:20804583; http://dx.doi.org/10.1186/1423- 0127-17-S1-S1.
23. Candiota A P, Majós C, Julià-Sapé M, Cabañas M, Acebes JJ, Moreno-Torres A, et al. Non-invasive grading of astrocytic tumours from the relative contents of myo-inositol and glycine measured by in vivo MRS. JBR-BTR 2011;94:319-29; PMID:22338386.
24. Hekmatyar SK, Wilson M, Jerome N, Salek RM, Griffin JL, Peet A, et al. 1H nuclear magnetic resonance spectroscopy characterisation of metabolic phenotypes in the medulloblastoma of the SMO transgenic mice. Br J Cancer 2010;103:1297-304; PMID:20842126; http://dx.doi.org/10.1038/sj.bjc.6605890.
25. McLean MA, Sun A, Bradstreet TE, Schaeffer AK, Liu H, Iannone R, et al. Repeatability of edited lactate and other metabolites in astrocytoma at 3 T. J Magn Reson Imaging 2012;36:468-75; PMID:22535478; http://dx.doi.org/10.1002/ jmri.23673.
26. Saraswathy S, Crawford FW, Lamborn KR, Pirzkall A, Chang S, Cha S, et al. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J Neurooncol 2009;91:69-81; PMID:18810326; http://dx.doi.org/10.1007/s11060-008-9685-3.
27. Howe FA, Opstad KS. 1H MR spectroscopy of brain tumours and masses. NMR Biomed 2003;16:123-31; PMID:12884355; http://dx.doi.org/10.1002/nbm.822. (Pubitemid 36950057)
28. Fricke S T, Vink R, Chiodo C, Cernak I, Ileva L, Faden AI. Consistent and reproducible slice selection in rodent brain using a novel stereotaxic device for MRI. J Neurosci Methods 2004;136:99-102; PMID:15126050; http://dx.doi.org/ 10.1016/j.jneu-meth.2004.01.003. (Pubitemid 38569876)
29. Avdeef A, Testa B. Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques. Cell Mol Life Sci 2002;59:1681-9; PMID:12475179; http://dx.doi.org/10.1007/PL00012496. (Pubitemid 35346972)
30. Alelyunas Y W, Pelosi-Kilby L, Turcotte P, Kary MB, Spreen RC. A high throughput dried DMSO LogD lipophilicity measurement based on 96-well shake-flask and atmospheric pressure photoionization mass spec-trometry detection. J Chromatogr A 2010;1217:1950-5; PMID:20153476; http://dx.doi.org/10. 1016/j. chroma.2010.01.071.
31. Casimiro M, Rodriguez O, Pootrakul L, Aventian M, Lushina N, Cromelin C, et al. ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo. Cancer Res 2007;67:4364-72; PMID:17483350; http://dx.doi.org/10. 1158/0008-5472. CAN-06-1898. (Pubitemid 46815085)
32. Lai EW, Rodriguez OC, Aventian M, Cromelin C, Fricke S T, Martiniova L, et al. ErbB-2 induces bilateral adrenal pheochromocytoma formation in mice. Cell Cycle 2007;6:1946-50; PMID:17671425; http://dx.doi.org/10.4161/cc.6.15.4521. (Pubitemid 47327914)
33. Rodriguez OC, Lai E W, Vissapragada S, Cromelin C, Avetian M, Salinas P, et al. A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1. Am J Pathol 2009;174:2051-60; PMID:19443706; http://dx.doi.org/10.2353/ajpath.2009.080859.
34. Vissapragada S, Ghosh A, Ringer L, Salinas P, Brophy A, Peaceman D, et al. Dietary n-3 polyunsaturated fatty acids fail to reduce prostate tumorigenesis in the PB-ErbB-2 x Pten (+/-) preclinical mouse model. Cell Cycle 2010;9:1824-9; PMID:20404514; http://dx.doi.org/10.4161/cc.9.9.11542.